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0196-6553/© 2019 Association for Professionals in InfectBackground: An important emerging respiratory virus is the Middle East respiratory syndrome coronavirus
(MERS-CoV). MERS-CoV had been associated with a high case fatality rate especially among severe cases.
Methods: This is a retrospective analysis of reported MERS-CoV cases between December 2016 and
January 2019, as retrieved from theWorld Health Organization. The aim of this study is to examine the epidemi-
ology of reported cases and quantify the percentage of health care workers (HCWs) among reported cases.
Results: There were 403 reported cases with a majority being men (n = 300; 74.4%). These cases were
reported from Lebanon, Malaysia, Oman, Qatar, Saudi Arabia, and United Arab Emirates. HCWs represented
26% and comorbidities were reported among 71% of non-HCWs and 1.9% among HCWs (P < .0001). Camel
exposure and camel milk ingestion were reported in 64% each, and the majority (97.8%) of those with camel
exposures had camel milk ingestion. There were 58% primary cases and 42% were secondary cases. The case
fatality rate was 16% among HCWs compared with 34% among other patients (P = .001). The mean age § SD
was 47.65 § 16.28 for HCWs versus 54.23 § 17.34 for non-HCWs (P = .001).
Conclusions:MERS-CoV infection continues to have a high case fatality rate and a large proportion of patients
were HCWs. Further understanding of the disease transmission and prevention mainly in health care settings
are needed.
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Middle East respiratory syndrome coronavirus (MERS-CoV). The virus
was initially described in a patient from Saudi Arabia in 2012,1 and
subsequently caused a spectrum of infections, from asymptomatic to
mild infections,2 and may result in a life threatening disease with a
high case fatality rate.3 As reported by the World Health Organization,
the virus caused a total of 2,279 laboratory-confirmed cases from 27
countries with a case fatality rate of 35%, as of the end of February
2019.4 Multiple health care−associated outbreaks were described
mainly in the Kingdom of Saudi Arabia5,6 and 1 large outbreak in South
Korea spanning >17 health care settings.7,8 In a systematic screeningof all admitted patients with community-acquired pneumonia to a
hospital in Saudi Arabia, only 20 (0.74%) of 2,657 screened patients
were positive for MERS-CoV by polymerase chain reaction testing.9
The spectrum of MERS-CoV infection ranges from mild to severe
and fulminant infections with severe acute respiratory disease.5,6 In
addition, a large proportion of asymptomatic cases were reported
specifically in children.2 There have been multiple studies of the epi-
demiology and clinical disease; however, there are no recent data on
the epidemiology of MERS-CoV in the last few years. Here, we ana-
lyzed publicly available MERS-CoV data to evaluate epidemiology of
MERS-CoV in the last 2 years.
METHODS
This is a retrospective analysis of reported cases between
December 2016 and January 2019. All reported MERS-CoV cases
were obtained from the World Health Organization Web site. These
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line listing.10 Statistical analysis was done using Minitab version
17 software (Minitab, State College, PA). A significant P value was
considered for P <.05. Boxplots of time to specified events were
generated as follows: lapsed time from onset of symptoms to
hospitalization, onset of symptoms to confirmation of diagnosis,
hospitalization to confirmation of diagnosis, and from onset of
symptoms to death. These times (in days) were calculated based
on the differences between the date of symptoms onset, date of
hospitalization, date of diagnosis confirmation, and date of death
(if this was the case).
We used publicly reported anonymized case-patient data
reported to the World Health Organization, therefore, there was no
requirement for informed consent or institutional review board
approval.
RESULTS
In the study period, there was a total of 403 reported cases with a
majority being men (n = 300; 74.4%). The mean age § SD was 52.5 §
17.3 years. These cases were reported from Lebanon (n = 1, 0.25%),Fig 1. Line graph showing monthly Middle East respiratory syndr
Fig 2. Boxplot of time to specified events and was calculated as follows: lapsed time from
hospitalization to confirmation of diagnosis, and from onset of symptoms to death. These ti
onset, date of hospitalization, date of diagnosis confirmation, and date of death (if this was thMalaysia (n = 1, 0.25%), Oman (n = 8, 2%), Qatar (n = 3, 0.74%), Saudi
Arabia (n = 382, 90.6%), and United Arab Emirates (n = 8, 2%). A line
graph of the distribution of cases over time is shown in Figure 1.
Of all the cases, there were 105 (26%) among health care workers
(HCWs). Comorbidities were reported among 214 (53%) cases with
no available information on 9% of cases. Data on camel exposure
were available for 245 cases and 157 (64%) had camel exposure.
Although camel milk consumption was reported for 151 cases and
64% did have camel milk ingestion, the majority (97.8%) of those with
camel exposures had camel milk ingestion. Classification of MERS-
CoV infection was reported for 212 cases; 58% were primary cases
and the others (42%) were secondary cases.
Figure 2 shows boxplot of time to specified events for lapsed
time from onset of symptoms to hospitalization, onset of symp-
toms to diagnosis, and onset to death. The case fatality rate was
29.3% in general, and there was a significant difference in the case
fatality rates between HCWs (16%) and others (34%) (P = .001). The
presence of comorbidities was 71% among non-HCWs and 1.9%
among HCWs (P < .0001). In addition, the mean age § SD was
47.65 § 16.28 for HCWs versus 54.23 § 17.34 for non-HCWs
(P = .001).ome coronavirus cases from December 2016 to January 2019.
onset of symptoms to hospitalization, onset of symptoms to confirmation of diagnosis,
mes (in days) were calculated based on the differences between the date of symptoms
e case). confirm, confirmation; hosp, hospitalization; TAT, turnaround time.
Table 1
A comparison of primary and secondary cases
Primary cases Secondary cases P value
Number 136 100
Age mean § SD 57.5 § 16.3 24.8 § 15.8 <.0001
Male, N (%) 114 (83) 54 (54) <.0001
Health care workers, N (%) 1 (0.74) 42 (42) <.0001
Comorbidities, N (%) 108 (82) 31 (45) <.0001
Camel exposure, N (%) 79/85 (92) 77/107 (72) <.0001
Death, N (%) 51 (37.5) 14 (14) <.0001
J.A. Al-Tawfiq, Z.A. Memish / American Journal of Infection Control 47 (2019) 1167−1170 1169A comparison between primary and secondary cases is shown in
Table 1 and Figure 3. Primary cases were older with higher comorbid-
ities, male sex, and case fatality rate. However, secondary cases were
more likely to be HCWs.
DISCUSSION
The total reported cases in the last 2 years was 403 and constitutes
17.6% of all reported cases. These were reported from 6 countries:
Lebanon, Malaysia, Oman, Qatar, Saudi Arabia, and United Arab
Emirates. However, there was a continued decline in the monthly
number of cases. It had also been shown that there was a negative
trend and reduction in monthly numbers of primary MERS-CoV cases
over a 3-year period from 2015-2017.11 This continued reduction in
the number of cases is primarily owing to containments of the cases
and prevention of health care−associated outbreaks.12 It was also
projected that primary MERS-CoV cases would decrease to 5 cases in
the spring of 2019.11
In the current analysis, a large proportion of cases were among
HCWs. The amplification of MERS-CoV is well known to occur in
health care settings as the hallmark of its transmission.12 In previ-
ous studies, HCWs represent an important fraction of people with
MERS-CoV infection with a reported rate of 14%-64%.13 From
September 2012 to July 2017, of the total cases, 2,040 (31%) were
health care facility-associated infections.14 The present study
showed that 26% were among HCWs. During the study period
2017-2018, there was a large outbreak in Saudi Arabia in June
2017 involving 3 health care settings.15-17 The most common routeFig 3. Interval plot of age versus exposure to MERS-CoV cases. CI, confidenof transmission of MERS-CoV to HCWs is health care−acquired
infections from patients to HCWs.5,18-25 There are multiple factors
contributing to the transmission within health care facilities
and these factors were recently reviewed12 and are clearly
reported,5,18,19,21 as summarized in a previous study.12 Therefore,
all health care facilities should adopt strategies for early detection
and isolation of patients suspected to have MERS-CoV infec-
tion.13,20,26 HCWs with MERS-CoV infection were either asymp-
tomatic or had mild disease, and fatal cases were described.27
Transmission of MERS-CoV among HCWs was reported to result
from asymptomatic HCWs.27
The presence of comorbidities was seen in 53% of patients in
the current study, and it was reported that severe disease tends
to occur in people with comorbid diseases and the elderly.28 The
case fatality rate in the current study is 29.3%, and seems to be
within the previously reported rates of 28%-64%.29,30 However,
higher case fatality rate was attributed to the inclusion of symp-
tomatic and critical ill patients,30 and the identification of more
asymptomatic cases resulted in reduction in the case fatality rate
from 64%-30%.6,20,31,32 HCWs with MERS-CoV had a lower fatality
rate of 7%.33
Of those with known camel exposure in the study, 64% had
camel exposure mainly as camel milk ingestion. There are multiple
studies describing the relationship between camel exposure and
MERS-CoV infection. The rate of camel exposure was variable in
different studies from 1.7% in a study of 70 cases to 4.3% in a study
of 161.32 In a study of 348 primary MERS-CoV cases, 191 (54.9%)
had contact with dromedaries.34 It is known that the calving sea-
son for dromedaries is November and March.31,35-37 In 1 study, the
prevalence of MERS-CoV was higher among camels in the winter
time (71.5%) than the summer time (6.2%).38 However, the current
cases occurred at a high number in May and June 2017 and not the
winter time.
The study showed interesting points in relation to primary cases
in that these patients were older and had higher case fatality rate
and comorbidities. The finding is similar to previous analysis of
MERS-CoV cases.34 These differences reflect different risks as pri-
mary cases occur frequently among camel exposures and in the
community, whereas secondary cases occur mainly in the health
care settings with a high rate of young HCWs.ce interval;MERS-CoV, Middle East respiratory syndrome coronavirus.
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There remains a large number of MERS-CoV in 2017 and 2018,
with a decreasing number over time. HCWs constitute a high-risk
group owing to continued exposure at health care settings. Primary
cases are older and have a higher case fatality rate. It is important to
screen exposed HCWs prior to allowing them to resume medical
duties and multiple samples may be needed. In addition, there is a
need for continued vigilance and identification of suspected cases.References
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